Today: June 18, 2018, 1:24 pm
  
Health

Grant programme for publications of oncolytic virotherapy announced

Grant programme announcement The International Virotherapy Center announces a grant programme for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy with Rigvir.
Oncolytic virotherapy
Oncolytic virotherapy
PR-Inside.com: 2016-07-05 12:37:41
Grant programme announcement

The International Virotherapy Center announces a grant programme for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy.

1. The grant programme up to a maximum of 3000 EUR for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy in a Pubmed indexed journal.


2. The grant programme to a maximum of 1000 EUR for publication of prospective or retrospective clinical research, and case reports on oncolytic virotherapy in a popular science journal.

Competition rules:

The grant application is open for all scientists except employees of the IVC and related organizations.

The grant is awarded after publication of the respective manuscript.

The research described should be about the use of Rigvir, not the use of Rigvir in combination with other drugs, food supplements etc.

Applicants are encouraged to apply for an early opinion on feasibility of the project; a draft manuscript should be provided prior to submission to a journal.

Applications and draft manuscript files not larger than 10 MB should be sent to: peteris@virotherapy.eu

The International Virotherapy Center (IVC) was founded to co-ordinate and promote oncolytic virotherapy worldwide. The mission of the IVC is to provide cancer virotherapy to every patient who would benefit from it. One of the most important objectives of IVC is to support research in the oncolytic virotherapy field and to establish the knowledge base for the practical use of oncolytic virotherapy.

Oncolytic virotherapy is cancer treatment with a specific virus which entering the human body is able to find and destroy malignant tumour cells. Rigvir has been approved for treatment of melanoma; however, in clinical practice it has been widely used for treatment of several other malignant tumours. Since 2015, Rigvir has been included in clinical guidelines approved by the Latvian National Health Service. Meanwhile, the patients from countries, where this medicine has not yet been approved, may receive the virotherapy with Rigvir as medical tourists. Currently, cancer patients from over 50 countries have already received virotherapy with Rigvir.

Press Information
International Virotherapy Center
Teatra 9, Riga

LV-1050

Latvia

Valdis Točs
Head of Communications
+371 26159666
email
www.rigvir.com


# 358 Words
Related Articles
 
More From Health
Novotech Signs MOU with China Medical University [..]
SYDNEY, AUS, June 12, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech announced today it has signed a Memorandum [..]
Regional Dentistry Practice Launches New Informational Website
Mishawaka, IN; June 13, 2018 – Coulter Family Dentistry today announced the complete redesign and relaunch of the practice’s website [..]
Darren Shanahan Grows Dental Broker Services & [..]
Summary: With the continued demand for support through dental practice transitions, valuations, planning and consulting – [..]
Avail Dental Exit Advisory Services Celebrates 7 [..]
Summary: Avail Dental Exit Advisory Services comes into its 7th year as a Dental Broker and continues to serve clients [..]
What Is Fentanyl? And, Why You Should [..]
The introduction of Fentanyl into the UK’s Heroin market has had a devastating impact on the number of opioid related [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.